Core Viewpoint - Four Seasons Pharmaceutical (00460) anticipates significant revenue growth, projecting at least 2.5 billion RMB in revenue and a net profit of at least 150 million RMB for the fiscal year ending December 31, 2025, driven primarily by its aesthetic medicine business and innovative drug segment [1] Group 1: Financial Performance - The company expects revenue growth exceeding 30% compared to the same period last year, with a projected revenue of no less than 2.5 billion RMB [1] - The net profit is anticipated to be at least 150 million RMB, indicating a strong financial outlook [1] Group 2: Business Segments - The aesthetic medicine segment is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing annual growth rates exceeding 90% [1] - The innovative drug business is entering a harvest phase, significantly improving the company's profit structure [1] Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves, having executed multiple rounds of share buybacks [1] - The successful spin-off of Xuan Zhu Bio has optimized the company's financial structure, contributing to profit breakthroughs [1]
四环医药盈喜后涨超6% 预期全年收入增速超30% 净利润不低于1.5亿元